The monoclonal antibody GNbAC1: targeting human endogenous retroviruses in multiple sclerosis.

ABSTRACT:

Background

Multiple sclerosis (MS) is an autoimmune demyelinating disorder of the central nervous system (CNS). Despite improvements of immunomodulatory therapies in relapsing-remitting MS, the pathomechanisms of progressive disease are poorly understood and therapeutically addressed to date. A pathophysiological role for proteins encoded by human endogenous retroviruses (HERVs) has been proposed. GNbAC1 is a monoclonal antibody directed against the envelope protein of a HERV with postulated involvement in MS.

Methods

This review addresses the treatment concept of GNbAC1, the design, preclinical and clinical development of the antibody, as published by November 2018. All four in-human trials (of which two addressed MS) are discussed.

Conclusion

The treatment concept o

SUBMITTER: Diebold M 

PROVIDER: S-EPMC6407165 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature